Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.

The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients.

Subsidie
€ 4.137.668
2023

Projectdetails

Introduction

Dilated Cardiomyopathy (DCM) is a heart muscle disorder characterised by thinning and stretching of the heart ventricles, making it harder for the heart to pump blood (systolic dysfunction). This disorder, with an estimated prevalence of up to 1/250, predominantly affects younger adults. It is associated with significant morbidity and mortality, including heart failure and sudden cardiac death, with end-stage DCM being the leading indication for heart transplantation.

Disease Burden

The current disease burden in DCM is largely attributable to two important gaps in scientific knowledge:

  1. Our understanding of the aetiology and genetic architecture of DCM remains limited, hindering the utility of genetic testing in clinical patient management.
  2. There are limited therapeutic options for DCM patients. Existing therapies are generic and target symptoms. No curative treatments exist, apart from invasive heart transplantation, and there are no approved therapies targeting underlying molecular disease mechanisms.

A fuller understanding of the genetic architecture of DCM and knowledge of the genes and genetic variants involved are critically needed to provide solutions for these unmet medical needs.

DCM-NEXT Consortium

The DCM-NEXT consortium combines world-leading interdisciplinary expertise and resources of 8 investigators in the fields of DCM, deep clinical phenotyping, cardiogenomics, cardiac transcriptomics, artificial intelligence, in silico drug target discovery, and functional studies. They will uniquely leverage their unparalleled cohort of 11,750 DCM probands and relatives with extensive clinical and omics data.

Project Aims

Through cutting-edge genomic and cardiac transcriptomic studies, the project aims to:

  1. Revolutionise genetic testing and patient stratification for more precise prediction of disease onset, progression, and risk of major adverse cardiac events.
  2. Accelerate the development of novel therapies by identifying and validating targets involved in the pathogenesis of DCM.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 4.137.668
Totale projectbegroting€ 4.137.718

Tijdlijn

Startdatum1-10-2023
Einddatum30-9-2027
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • STICHTING AMSTERDAM UMCpenvoerder
  • MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)
  • CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)
  • SERVICIO MADRILENO DE SALUD
  • UNIVERSITEIT MAASTRICHT
  • FONDATION CARDIOMETABOLISME NUTRITION
  • FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO PUERTA DE HIERRO-MAJADAHONDA
  • IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Land(en)

NetherlandsGermanySpainFranceUnited Kingdom

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions

CARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes.

€ 4.349.410
EIC Pathfinder

Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment

The project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies.

€ 3.740.868
EIC Pathfinder

A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarction

TargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation.

€ 3.999.840
EIC Pathfinder

B-specific: B-cell related gene and protein markers with prognostic and therapeutic value for CVD

The B-specific consortium aims to identify and target specific B-cell subsets to develop personalized therapies for atherosclerosis and improve cardiovascular disease risk assessment and management.

€ 4.006.599
EIC Pathfinder

MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEase

The MIRACLE project aims to develop advanced multiomics-based risk prediction models for atherosclerotic cardiovascular disease by integrating genetic data and biomarkers for improved early diagnosis and treatment.

€ 4.000.000

Vergelijkbare projecten uit andere regelingen

ERC Proof of...

Universal Cardiac Mesoangioblasts for treating DMD Dilated Cardiomyopathy

The project aims to develop immune-privileged cardiac mesoangioblasts that can be converted to cardioblasts for targeted treatment of dilated cardiomyopathy, enhancing heart repair.

€ 150.000
ERC Starting...

Development of novel 3D vascularized cardiac models to investigate Coronary Microvascular Disease

The 3DVasCMD project aims to develop a 3D vascularized cardiac model using iPSC technology to study coronary microvascular disease and identify therapeutic targets for improved cardiovascular health.

€ 1.496.395
ERC Consolid...

Dynamic engIneered heart tiSsue to Study intEr-individual susCeptibily and improve Treatment of Heart Failure

DISSECT-HF aims to engineer heart tissue from patient-specific stem cells to uncover common mechanisms of heart failure across different etiologies and improve treatment strategies.

€ 1.998.775
ERC Advanced...

The transcriptional regulation of cardiomyocyte polyploidization and its relevance in cardiac regeneration

REACTIVA aims to promote heart regeneration by reactivating adult diploid cardiomyocytes through a newly identified regulatory network and inhibiting a specific transcription factor.

€ 2.500.000
ERC Advanced...

Advanced human models of the heart to understand cardiovascular disease

Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.

€ 2.500.000